PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $380 | -8.4% | 12,087 | +4.1% | 0.01% | 0.0% |
| Q2 2023 | $415 | -12.8% | 11,611 | -0.4% | 0.01% | -18.2% |
| Q1 2023 | $476 | +20.2% | 11,660 | +13.7% | 0.01% | +10.0% |
| Q4 2022 | $396 | -99.9% | 10,256 | +6.1% | 0.01% | -28.6% |
| Q3 2022 | $514,000 | -10.6% | 9,662 | -1.9% | 0.01% | -6.7% |
| Q2 2022 | $575,000 | -23.9% | 9,853 | -0.5% | 0.02% | -11.8% |
| Q1 2022 | $756,000 | +171.9% | 9,903 | +114.4% | 0.02% | +183.3% |
| Q4 2021 | $278,000 | -51.4% | 4,620 | -54.8% | 0.01% | -53.8% |
| Q3 2021 | $572,000 | -8.5% | 10,210 | -0.9% | 0.01% | -13.3% |
| Q2 2021 | $625,000 | -14.9% | 10,300 | -1.6% | 0.02% | -16.7% |
| Q1 2021 | $734,000 | +19.3% | 10,470 | +1.8% | 0.02% | +12.5% |
| Q4 2020 | $615,000 | +133.8% | 10,280 | +135.2% | 0.02% | +128.6% |
| Q3 2020 | $263,000 | +19.5% | 4,370 | +4.0% | 0.01% | +16.7% |
| Q2 2020 | $220,000 | – | 4,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |